Testing Immunotherapies in Syngeneic Models

Charles River offers a broad range of syngeneic tumor models with well-characterized responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1 and anti-CTLA-4), making us the ideal partner to advance your immuno-oncology pipeline.

SYNGENEIC MODEL DATA
syngeneic mouse model, syngeneic model data

Access our syngeneic model data including check point inhibitor and whole exome sequencing (WES).

Download now

  • SYNGENEIC MODELS WITH PROFILE
    HistotypeCell Line
    BladderMBT-2
    BrainGL261
    Breast4T1, EMT-6
    ColonColon26, CT26, MC38
    LungKLN 205, Lewis Lung, Madison109
    LymphomaA20, E.G7-OVA
    MelanomaB16F10, CloudmanS91
    PancreaticPan02
    RenalRenca
  • SYNGENEIC MODELS WITHOUT PROFILE*
    HistotypeCell Line
    BreastEMT-6-BRCA1(−/−), EMT-6-BRCA1(+/−), 4T1-BRCA1(+/−)
    HepatomaYoshida
    LeukemiaC1498, L1210, P388
    LymphomaEL4
    MastocytomaP815
    PlasmacytomaJ558
    SarcomaEHS

    * Note: Although these models have not yet been profiled for response to current standards of care, tumor growth curve data is available.

Complementary Assays

To improve translational relevance, Charles River provides in vitro immuno-oncology assays that mimic this complex biology.